NasdaqCM:PIRS

Stock Analysis Report

Executive Summary

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Pieris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.6%

PIRS

0.8%

US Biotechs

1.0%

US Market


1 Year Return

-35.4%

PIRS

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: PIRS underperformed the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: PIRS underperformed the US Market which returned 6.7% over the past year.


Share holder returns

PIRSIndustryMarket
7 Day8.6%0.8%1.0%
30 Day-39.5%-3.9%-1.8%
90 Day-27.1%-3.5%-1.8%
1 Year-35.4%-35.4%-7.5%-8.3%9.1%6.7%
3 Year100.0%100.0%13.6%9.6%46.1%36.6%
5 Yearn/a3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is Pieris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pieris Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

8.29x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: PIRS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PIRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate PIRS's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: PIRS is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Pieris Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

-3.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: PIRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PIRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PIRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PIRS's revenue (31.3% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: PIRS's revenue (31.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if PIRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pieris Pharmaceuticals performed over the past 5 years?

-19.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PIRS is unprofitable, and losses have increased over the past 5 years at a rate of -19.2% per year.

Accelerating Growth: Unable to compare PIRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PIRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: PIRS has a negative Return on Equity (-204.99%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PIRS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PIRS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Pieris Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PIRS's short term assets ($111.5M) exceeds its short term liabilities ($40.9M)

Long Term Liabilities: PIRS's short term assets (111.5M) exceeds its long term liabilities (70.4M)


Debt to Equity History and Analysis

Debt Level: PIRS is debt free.

Reducing Debt: PIRS currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: PIRS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PIRS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PIRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PIRS has sufficient cash runway for 2.049858 years if free cash flow continues to reduce at historical rates of -25.2% each year.


Next Steps

Dividend

What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate PIRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PIRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PIRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PIRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PIRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Pieris Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Steve Yoder (43yo)

4.8yrs

Tenure

US$2,621,008

Compensation

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as  ...


CEO Compensation Analysis

Compensation vs. Market: Steve's total compensation ($USD2.62M) is about average for companies of similar size in the US market ($USD1.17M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.0yrs

Average Tenure

44.5yo

Average Age

Experienced Management: PIRS's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Age and Tenure

1.8yrs

Average Tenure

58yo

Average Age

Experienced Board: PIRS's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$224,97010 Sep 19
BVF Partners LP
EntityCompany
Shares50,000
Max PriceUS$4.50

Ownership Breakdown


Management Team

  • Louis Matis (68yo)

    Senior VP & Chief Development Officer

    • Tenure: 4.2yrs
    • Compensation: US$1.12m
  • Claus Schalper

    Co-Founder & Senior Advisor

    • Tenure: 2.2yrs
  • Steve Yoder (43yo)

    CEO, President & Director

    • Tenure: 4.8yrs
    • Compensation: US$2.62m
  • Allan Reine (44yo)

    • Tenure: 0.08yrs
    • Compensation: US$871.26k
  • Christine Rothe

    Head of Discovery & Alliance Management and VP

    • Tenure: 0yrs
  • Ahmed Mousa

    VP, General Counsel & Corporate Secretary

    • Tenure: 2.4yrs
  • Frank Vollmering

    Vice President of Human Resources

    • Tenure: 1.8yrs
  • Maria Kelman

    Director of Investor Relations

    • Tenure: 0yrs
  • Hitto Kaufmann

    Senior VP & Chief Scientific Officer

    • Tenure: 0.2yrs
  • Tom Bures (45yo)

    Principal Financial & Accounting Officer and Treasurer

    • Tenure: 0.08yrs

Board Members

  • Jim Geraghty (64yo)

    Chairman

    • Tenure: 1.8yrs
    • Compensation: US$199.86k
  • Michael Richman (58yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$144.40k
  • Chris Kiritsy (54yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: US$152.76k
  • Peter Kiener (67yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$105.52k
  • Matt Sherman (63yo)

    Director

    • Tenure: 1yrs
    • Compensation: US$99.96k
  • Steve Yoder (43yo)

    CEO, President & Director

    • Tenure: 4.8yrs
    • Compensation: US$2.62m
  • Ann Barbier (55yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$154.03k
  • Jean-Pierre Bizzari (65yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$139.95k
  • Maya Said (42yo)

    Director

    • Tenure: 0.2yrs

Company Information

Pieris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pieris Pharmaceuticals, Inc.
  • Ticker: PIRS
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$162.008m
  • Shares outstanding: 49.39m
  • Website: https://www.pieris.com

Number of Employees


Location

  • Pieris Pharmaceuticals, Inc.
  • 255 State Street
  • 9th Floor
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PIRSNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDDec 2014
PI6DB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2014

Biography

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 02:59
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)